Bill Few Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.22M Sell
1,850
-302
-14% -$309K 0.47% 54
2026
Q1
$1.98M Sell
2,152
-69
-3% -$70K 0.47% 54
2025
Q4
$2.39M Sell
2,221
-40
-2% -$38.2K 0.59% 45
2025
Q3
$1.73M Sell
2,261
-17
-0.7% -$12.7K 0.44% 52
2025
Q2
$1.78M Sell
2,278
-143
-6% -$111K 0.5% 52
2025
Q1
$2M Buy
2,421
+296
+14% +$246K 0.71% 42
2024
Q4
$1.64M Sell
2,125
-85
-4% -$70.4K 0.58% 47
2024
Q3
$1.96M Sell
2,210
-171
-7% -$154K 0.69% 42
2024
Q2
$2.16M Sell
2,381
-123
-5% -$98.4K 0.83% 36
2024
Q1
$1.95M Buy
2,504
+392
+19% +$279K 0.79% 35
2023
Q4
$1.23M Buy
2,112
+98
+5% +$57.2K 0.56% 48
2023
Q3
$1.08M Sell
2,014
-20
-1% -$10.3K 0.57% 45
2023
Q2
$954K Sell
2,034
-100
-5% -$41.9K 0.49% 48
2023
Q1
$733K Buy
2,134
+100
+5% +$33.7K 0.41% 53
2022
Q4
$744K Hold
2,034
0.44% 50
2022
Q3
$657K Hold
2,034
0.44% 52
2022
Q2
$659K Hold
2,034
0.42% 51
2022
Q1
$582K Sell
2,034
-150
-7% -$38.6K 0.32% 59
2021
Q4
$603K Buy
+2,184
New +$554K 0.31% 58

Other funds holding LLY

Bill Few Associates's LLY Position: Q2 2026 in Review

Bill Few Associates reduced its Eli Lilly (LLY) stake by 14% in Q2 2026, selling an estimated $309K and leaving 1,850 shares worth $2.22M. The position accounts for 0.47% of the portfolio, ranked #54.

Bill Few Associates first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.39M in Q4 2025. 841 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Bill Few Associates held 1,850 shares of Eli Lilly worth $2.22M as of Q2 2026.
  • Bill Few Associates sold 302 Eli Lilly shares in Q2 2026, an estimated $309K.
  • Eli Lilly made up 0.47% of Bill Few Associates's portfolio in Q2 2026, its #54 holding.
  • Bill Few Associates first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • Bill Few Associates's Eli Lilly position peaked at $2.39M in Q4 2025.
  • 841 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Bill Few Associates's 13F filing for Q2 2026, filed 7 Jul 2026.